Population Pharmacokinetics of Clinafloxacin in Healthy Volunteers and Patients with InfectionsExperience with Heterogeneous Pharmacokinetic Data

被引：0
|
作者：
Bill Frame
Jeffrey Koup
Raymond Miller
Richard Lalonde
机构：
[1] PfizerGlobal Research and Development,Department of Clinical Pharmacokinetics and Pharmacodynamics
来源：
Clinical Pharmacokinetics | 2001年 / 40卷
关键词：
Mixed Effect Modelling; Interindividual Variability; Intraindividual Variability; Clinafloxacin; Combine Phase;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: Clinafloxacin is a new fluoroquinolone antibacterial with inhibitory activity against aerobic, anaerobic and atypical bacterial pathogens. The objectives of this study are to evaluate the pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections and to describe our experience with mixed-effects modelling using heterogeneous pharmacokinetic data.
引用
收藏
页码：307 / 315
页数：8
相关论文
共 50 条
  • [1] Population pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections - Experience with heterogeneous pharmacokinetic data
    Frame, B
    Koup, J
    Miller, R
    Lalonde, R
    CLINICAL PHARMACOKINETICS, 2001, 40 (04) : 307 - 315
  • [2] Population pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections: experience with heterogeneous pharmacokinetic data. (vol 40, pg 307, 2001)
    Frame, B
    Koup, J
    Miller, R
    Lolonde, R
    CLINICAL PHARMACOKINETICS, 2001, 40 (07) : 537 - 537
  • [3] Effect of age on clinafloxacin pharmacokinetics in healthy volunteers
    Randinitis, EJ
    Abel, R
    Bron, NJ
    Hounslow, NJ
    Rausch, G
    Vassos, AB
    DRUGS, 1999, 58 (Suppl 2) : 246 - 247
  • [4] Effect of Age on Clinafloxacin Pharmacokinetics in Healthy Volunteers
    E. J. Randinitis
    R. Abel
    N. J. Bron
    N. J. Hounslow
    G. Rausch
    A. B. Vassos
    Drugs, 1999, 58 : 246 - 247
  • [5] Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
    Neeraj Gupta
    Xiaohui Wang
    Elliot Offman
    Marita Prohn
    Narayana Narasimhan
    David Kerstein
    Michael J. Hanley
    Karthik Venkatakrishnan
    Clinical Pharmacokinetics, 2021, 60 : 235 - 247
  • [6] Population Pharmacokinetics of Peramivir in Healthy Volunteers and Influenza Patients
    Matsuo, Yumiko
    Ishibashi, Toru
    Hollister, Alan S.
    Wajima, Toshihiro
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (11) : 6755 - 6762
  • [7] Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
    Gupta, Neeraj
    Wang, Xiaohui
    Offman, Elliot
    Prohn, Marita
    Narasimhan, Narayana
    Kerstein, David
    Hanley, Michael J.
    Venkatakrishnan, Karthik
    CLINICAL PHARMACOKINETICS, 2021, 60 (02) : 235 - 247
  • [8] Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients
    Hughes, Jim H.
    Qiu, Ruolun
    Banfield, Christopher
    Dowty, Martin E.
    Nicholas, Timothy
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (12): : 1447 - 1456
  • [9] The Influence of Sparse Data Sampling on Population Pharmacokinetics: A Post Hoc Analysis of a Pharmacokinetic Study of Morphine in Healthy Volunteers
    Ariano, Robert E.
    Duke, Peter C.
    Sitar, Daniel S.
    CLINICAL THERAPEUTICS, 2012, 34 (03) : 668 - 676
  • [10] Population pharmacokinetic analysis of pirmenol in healthy volunteers and patients with arrhythmia
    Kasai, H
    Ueno, K
    Kusumoto, M
    Shibakawa, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (01) : 77 - 78
12345